NASDAQ:KPTI Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free KPTI Stock Alerts $1.08 0.00 (0.00%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$1.05▼$1.1350-Day Range$1.03▼$1.5852-Week Range$0.62▼$3.78Volume974,953 shsAverage Volume1.60 million shsMarket Capitalization$125.79 millionP/E RatioN/ADividend YieldN/APrice Target$5.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Karyopharm Therapeutics alerts: Email Address Karyopharm Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside424.7% Upside$5.67 Price TargetShort InterestBearish20.23% of Shares Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$206,118 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.19) to ($1.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.08 out of 5 starsMedical Sector347th out of 908 stocksPharmaceutical Preparations Industry154th out of 419 stocks 3.3 Analyst's Opinion Consensus RatingKaryopharm Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageKaryopharm Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted20.23% of the outstanding shares of Karyopharm Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in Karyopharm Therapeutics has recently increased by 2.66%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKaryopharm Therapeutics has received a 71.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Other cancer medication", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Karyopharm Therapeutics is -1.11. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Karyopharm Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for KPTI on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $206,118.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($1.19) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Karyopharm Therapeutics Stock (NASDAQ:KPTI)Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Read More KPTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KPTI Stock News HeadlinesMay 2, 2024 | prnewswire.comKaryopharm to Report First Quarter 2024 Financial Results on May 8, 2024May 1, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.April 24, 2024 | prnewswire.comKaryopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual MeetingApril 1, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 15, 2024 | finance.yahoo.comKPTI Apr 2024 5.000 callMarch 15, 2024 | finance.yahoo.comKPTI Apr 2024 1.500 putMarch 14, 2024 | businesswire.comOnco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO ® (selinexor)May 2, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.March 6, 2024 | finance.yahoo.comKaryopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma ConferencesMarch 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Siemens Healthineers AG (OtherSEMHF)March 5, 2024 | finance.yahoo.comInsider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...March 2, 2024 | seekingalpha.comKaryopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | fool.comKaryopharm Therapeutics (KPTI) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finance.yahoo.comQ4 2023 Karyopharm Therapeutics Inc Earnings CallFebruary 29, 2024 | finanznachrichten.deKaryopharm Therapeutics Inc.: Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressFebruary 29, 2024 | msn.comKaryopharm Therapeutics GAAP EPS of -$0.36 misses by $0.07, revenue of $33.7M beats by $0.08MFebruary 29, 2024 | markets.businessinsider.comKaryopharm Therapeutics Inc. Q4 Loss misses estimatesFebruary 29, 2024 | finance.yahoo.comKaryopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressFebruary 28, 2024 | benzinga.comKaryopharm Therapeutics's Earnings: A PreviewFebruary 27, 2024 | finance.yahoo.comKPTI Mar 2024 1.000 putFebruary 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: FibroGen (FGEN), Karyopharm Therapeutics (KPTI) and Day One Biopharmaceuticals (DAWN)February 25, 2024 | ca.finance.yahoo.comKPTI Mar 2024 1.500 callFebruary 25, 2024 | investorplace.com7 Biotech Penny Stocks on the Verge of Clinical Trial VictoryFebruary 23, 2024 | benzinga.comKaryopharm Therapeutics Stock (NASDAQ:KPTI) Earnings Dates and Earning CallsSee More Headlines Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/02/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KPTI CUSIPN/A CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees325Year FoundedN/APrice Target and Rating Average Stock Price Target$5.67 High Stock Price Target$10.00 Low Stock Price Target$3.00 Potential Upside/Downside+424.7%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-143,100,000.00 Net Margins-97.99% Pretax Margin-97.77% Return on EquityN/A Return on Assets-50.47% Debt Debt-to-Equity RatioN/A Current Ratio3.37 Quick Ratio3.32 Sales & Book Value Annual Sales$146.03 million Price / Sales0.86 Cash FlowN/A Price / Cash FlowN/A Book Value($1.19) per share Price / Book-0.91Miscellaneous Outstanding Shares116,470,000Free Float111,458,000Market Cap$125.79 million OptionableOptionable Beta0.16 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Richard A. Paulson M.B.A. (Age 57)President, CEO & Director Comp: $1.36MDr. Sharon Shacham M.B.A. (Age 54)Ph.D., Co-Founder & Chairman of Scientific Advisory Board Comp: $1.4MMr. Michael P. Mason CPA (Age 49)M.B.A., Executive VP, CFO & Treasurer Comp: $681.59kMr. Michael J. Mano J.D. (Age 47)Senior VP, General Counsel & Secretary Comp: $625.08kMs. Sohanya Cheng M.B.A. (Age 41)Executive VP & Chief Commercial Officer Comp: $664.3kMr. Stuart PoultonExecutive VP & Chief Development OfficerDr. Mansoor Raza Mirza M.D. (Age 63)Clinical Consultant, Member of Scientific Advisory Board & Independent Director Comp: $150kMr. Cameron Peters (Age 64)Vice President of Finance, Assistant Treasurer & Principal Accounting Officer Ms. Elhan Webb C.F.A.Senior Vice President of Investor RelationsMr. James Accumanno J.D.Chief Compliance OfficerMore ExecutivesKey CompetitorsCartesian TherapeuticsNASDAQ:RNACCitius PharmaceuticalsNASDAQ:CTXRAdicet BioNASDAQ:ACETPDS BiotechnologyNASDAQ:PDSBAmylyx PharmaceuticalsNASDAQ:AMLXView All CompetitorsInsiders & InstitutionsSimplicity Wealth LLCBought 44,011 shares on 4/24/2024Ownership: 0.038%Reshma RangwalaSold 6,789 sharesTotal: $7,943.13 ($1.17/share)Richard A PaulsonSold 3,563 sharesTotal: $4,596.27 ($1.29/share)Richard A PaulsonSold 3,573 sharesTotal: $4,644.90 ($1.30/share)Richard A PaulsonSold 80,470 sharesTotal: $94,149.90 ($1.17/share)View All Insider TransactionsView All Institutional Transactions KPTI Stock Analysis - Frequently Asked Questions Should I buy or sell Karyopharm Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KPTI shares. View KPTI analyst ratings or view top-rated stocks. What is Karyopharm Therapeutics' stock price target for 2024? 5 Wall Street research analysts have issued 12-month price targets for Karyopharm Therapeutics' stock. Their KPTI share price targets range from $3.00 to $10.00. On average, they anticipate the company's stock price to reach $5.67 in the next year. This suggests a possible upside of 424.7% from the stock's current price. View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts. How have KPTI shares performed in 2024? Karyopharm Therapeutics' stock was trading at $0.8650 at the beginning of the year. Since then, KPTI shares have increased by 24.9% and is now trading at $1.08. View the best growth stocks for 2024 here. When is Karyopharm Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our KPTI earnings forecast. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) posted its earnings results on Thursday, February, 29th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.07. The business earned $33.75 million during the quarter, compared to analysts' expectations of $33.50 million. During the same period in the prior year, the company earned ($0.43) earnings per share. What guidance has Karyopharm Therapeutics issued on next quarter's earnings? Karyopharm Therapeutics updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $140.0 million-$160.0 million, compared to the consensus revenue estimate of $152.0 million. What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO? 31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY). Who are Karyopharm Therapeutics' major shareholders? Karyopharm Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Simplicity Wealth LLC (0.04%). Insiders that own company stock include Deepika Pakianathan, Garen G Bohlin, Jatin Shah, Michael Kauffman, Michael Mano, Michael Mason, Reshma Rangwala, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Stuart Poulton. View institutional ownership trends. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KPTI) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressYour bank is lying to you.MyBankTrackerTrump just won 2024Porter & CompanyA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap Profits4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.